Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLUSTOID Grasses/Rye Immunotherapy in Allergic Rhinoconjunctivitis
NCT01012531Phase 3Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Oct 2008
- Primary completion
- Nov 2009
- Modality
- Split/Subunit Vaccines, Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing CLUSTOID Grasses/Rye with Placebo (2 arms). Primary endpoint: Symptom and medication score at 1 year. Started Oct 2008; status: completed.
02
Drugs
polymerized grass pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01012531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012531.